Drug Trial Radar · NCT06548100
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Dec 16, 2024
Primary completion
Jul 9, 2026
Study completion Jul 9, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months. The aim of the study is to see how safe and tolerable mibavademab is when switching from treatment with metreleptin. The study is looking at several other research questions, including: * What side effects may happen from taking mibavademab * How much mibavademab is in the blood at different times * Whether the body makes antibodies against mibavademab (which could make mibavademab less effective or could lead to side effects)
Conditions
- Generalized Lipodystrophy
Interventions
mibavademabDrug
Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: Up to week 68
- Severity of TEAEsTime frame: Up to week 68
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Institutes of Health
Bethesda, Maryland
University of Michigan
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.